NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility
In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut
Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs
Don’t Blame FDA For All Problems, Broder Says
Outside Experts Might Lengthen NDA Approval, Peck Asserts
Freement Lists Steps For Dealing With Disadvantaged
Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - What happened at FDA? Replimune approval raises questions
- What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer - Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science









